Funds and ETFs Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
1.2 USD -6.98% Intraday chart for Lineage Cell Therapeutics, Inc. -14.89% +10.09%

ETFs positioned on Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.2 USD
Average target price
5.2 USD
Spread / Average Target
+333.33%
Consensus
  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. Funds and ETFs Lineage Cell Therapeutics, Inc.